You are here

FDA Okays Jetrea (Ocriplasmin) for Symptomatic Vitreomacular Adhesion

First drug approved for sight-threatening condition (Oct. 18)

The FDA has approved Jetrea (ocriplasmin, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA), a progressive sight-threatening condition.

Jetrea is the first pharmacological agent to be approved for this indication.

The drug’s recommended dose is 0.125 mg (0.1 mL) of the diluted solution administered by intravitreal injection to the affected eye once as a single injection. Jetrea is provided as a single-use glass vial containing 0.5 mg in 0.2 mL of solution for intravitreal injection (2.5 mg/mL).

The FDA approval was based on data from a phase III program in which Jetrea was shown to be superior to placebo for the treatment of symptomatic VMA (26.5% versus 10.1%, respectively; P

Symptomatic VMA is a progressive condition that, if left untreated, often leads to retinal distortion and further deterioration in vision that can ultimately result in irreversible damage. Market surveys suggest that approximately 500,000 patients in the U.S. and Europe may benefit from treatment with Jetrea each year.

The U.S. launch is scheduled for January 2013.

Source: ThromboGenics, October 18, 2012.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed